[Guidelines for the management of adverse effects of anti-seizure medications (2023)]
- PMID: 37718393
- PMCID: PMC10511233
- DOI: 10.7499/j.issn.1008-8830.2306016
[Guidelines for the management of adverse effects of anti-seizure medications (2023)]
Abstract
Epilepsy is a prevalent neurological disorder with a complex etiology and an unclear pathogenesis. In order to standardize the management of adverse effects caused by anti-seizure medications (ASMs), the Youth Committee of the Chinese Association Against Epilepsy (CAAE), in collaboration with the CAAE Precision Medicines and Adverse Effect Monitoring Committee, has developed a guideline: guidelines for the management of adverse effects of anti-seizure medications (2023). This guideline addresses 13 clinical questions related to the management of adverse effects of ASMs in the nervous system, cardiovascular system, and fetus. Its primary objective is to provide guidance to medical professionals specializing in pediatric neurology, neurology, and neurosurgery in China, and to facilitate their clinical practice.
癫痫是一种常见的神经系统疾病,病因复杂,发病机制尚未明确。为规范抗癫痫发作药物(anti-seizure medication, ASM)不良反应的管理,中国抗癫痫协会青年委员会联合中国抗癫痫协会精准医学与药物不良反应监测专业委员会组织制定了“抗癫痫发作药物不良反应管理指南(2023)”,对于ASM在神经精神系统、心血管系统及胎儿方面的不良反应管理,解答了13个临床问题,以期指导我国各医疗机构的癫痫专科、儿童神经科、神经内科、神经外科医务工作者的临床实践。.
Keywords: Adverse effect; Anti-seizure medication; Epilepsy; Management guideline.
Conflict of interest statement
本指南工作组所有成员声明不存在利益冲突。
References
-
- EEBM . OCEBM levels of evidence[EB/OL]. [2023-07-25]. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-e....
Publication types
LinkOut - more resources
Full Text Sources